TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

Core Insights - TG Therapeutics, Inc. announced the schedule for presentations on BRIUMVI® (ublituximab-xiiy) data for patients with relapsing forms of multiple sclerosis (RMS) at the AAN 2026 annual meeting [1][2] Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI® approved for treating adult patients with RMS in the U.S. and several other countries [27] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [3] - The product is indicated for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [4] Clinical Studies and Presentations - Upcoming presentations include data from the ENABLE Phase 4 observational study and updates from the ENHANCE study regarding the safety and tolerability of a modified dosing regimen [2][6] - The presentations will take place on April 21, 2026, during the AAN annual meeting [6] Safety Information - BRIUMVI has contraindications for patients with active Hepatitis B virus infection and a history of life-threatening infusion reactions [5][7] - Infusion reactions occurred in 48% of patients treated with BRIUMVI, with serious reactions in 0.6% of patients [5] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [9] Market Context - Relapsing multiple sclerosis (RMS) affects nearly 1 million people in the U.S., with approximately 85% initially diagnosed with relapsing-remitting multiple sclerosis [26]